Resumes
Resumes
Dawei Zhang Phones & Addresses
-
3030 Blazing Star Dr, Thousand Oaks, CA 91362 (805) 241-9436
-
Newbury Park, CA
-
Decatur, GA
-
Alhambra, CA
-
Atlanta, GA
-
San Diego, CA
-
Ventura, CA
Business Records
Name / Title
Company / Classification
Phones & Addresses
President
ABC Aero Parts, Inc
Whol Transportation Equipment
Whol Transportation Equipment
13576 Plascencia Ct, Duarte, CA 91706
President
YI WORLD, INC
Business Services at Non-Commercial Site · Nonclassifiable Establishments
Business Services at Non-Commercial Site · Nonclassifiable Establishments
18988 Barroso St, Rowland Heights, CA 91748
1214 Galemont Ave, Whittier, CA 91745
106 N Almansor St, Alhambra, CA 91801
1214 Galemont Ave, Whittier, CA 91745
106 N Almansor St, Alhambra, CA 91801
President
MARS INT'L ENTERPRISES, INC
951 S Meridian Ave, Alhambra, CA 91803
President
SUNRY INTERNATIONAL (L.A.), INC
402 W Grand Ave #C, Alhambra, CA 91801
President
SINA PLASTICS INC
9835 Max Shapiro Way, South El Monte, CA 91733
Principal
Mars International Enterp
Whol Lumber/Plywood/Millwork
Whol Lumber/Plywood/Millwork
951 S Meridian Ave, Alhambra, CA 91803
PO Box 812, Rosemead, CA 91770
PO Box 812, Rosemead, CA 91770
M
Westlake Sciences LLC
3030 Blazing Star Dr, Thousand Oaks, CA 91362
Publications
Us Patents
Substituted Heterocyclic Compounds And Methods Of Use
View pageUS Patent:
6967254, Nov 22, 2005
Filed:
Sep 8, 2003
Appl. No.:
10/658298
Inventors:
Celia Dominguez - Thousand Oaks CA, US
Dawei Zhang - Thousand Oaks CA, US
Kelvin K. C. Sham - Thousand Oaks CA, US
Guo-Qiang Cao - Thousand Oaks CA, US
Dawei Zhang - Thousand Oaks CA, US
Kelvin K. C. Sham - Thousand Oaks CA, US
Guo-Qiang Cao - Thousand Oaks CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
C07D401/04
C07D401/14
C07D401/14
US Classification:
5462761, 546194, 546256
Abstract:
The present invention relates to compounds having the general formula or a pharmaceutically acceptable salt thereof. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.
Substituted Heterocyclic Compounds And Methods Of Use
View pageUS Patent:
7026326, Apr 11, 2006
Filed:
May 13, 2003
Appl. No.:
10/438553
Inventors:
Guo-Qiang Cao - Thousand Oaks CA, US
Celia Dominguez - Thousand Oaks CA, US
Martin H. Goldberg - Woodlands Hills CA, US
Kelvin K. C. Sham - Thousand Oaks CA, US
Seifu Tadesse - Simi Valley CA, US
Nuria A. Tamayo - Newbury Park CA, US
Kurt E. Weiler - Thousand Oaks CA, US
Dawei Zhang - Thousand Oaks CA, US
Hongyu Liao - Thousand Oaks CA, US
Celia Dominguez - Thousand Oaks CA, US
Martin H. Goldberg - Woodlands Hills CA, US
Kelvin K. C. Sham - Thousand Oaks CA, US
Seifu Tadesse - Simi Valley CA, US
Nuria A. Tamayo - Newbury Park CA, US
Kurt E. Weiler - Thousand Oaks CA, US
Dawei Zhang - Thousand Oaks CA, US
Hongyu Liao - Thousand Oaks CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
A61K 31/505
US Classification:
514269, 544242
Abstract:
The present invention relates to compounds having the general formula or a pharmaceutically acceptable salt thereof, wherein Ris a saturated or unsaturated 5-, 6- or 7-membered, ring containing 0, 1, 2 or 3 atoms selected from N, O and S, wherein the ring may be fused with a benzo group, and is substituted by 0, 1 or 2 oxo groups, and wherein Ris additionally substituted; and Ris a substituted Calkyl. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.
Imidazo- And Triazolo-Pyridine Compounds And Methods Of Use Thereof
View pageUS Patent:
7700593, Apr 20, 2010
Filed:
Oct 5, 2007
Appl. No.:
11/973076
Inventors:
Dawei Zhang - Thousand Oaks CA, US
Andrew Tasker - Simi Valley CA, US
Kelvin K. C. Sham - Thousand Oaks CA, US
Partha Pratim Chakrabarti - Nagpur, IN
James Richard Falsey - Moorpark CA, US
Bradley J. Herberich - Newbury Park CA, US
Liping H. Pettus - Thousand Oaks CA, US
Robert M. Rzasa - Ventura CA, US
Andrew Tasker - Simi Valley CA, US
Kelvin K. C. Sham - Thousand Oaks CA, US
Partha Pratim Chakrabarti - Nagpur, IN
James Richard Falsey - Moorpark CA, US
Bradley J. Herberich - Newbury Park CA, US
Liping H. Pettus - Thousand Oaks CA, US
Robert M. Rzasa - Ventura CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
A61K 31/5377
C07D 221/02
A61K 31/496
A61P 29/00
C07D 295/00
A61K 31/437
C07D 221/02
A61K 31/496
A61P 29/00
C07D 295/00
A61K 31/437
US Classification:
5142332, 514303, 514300, 51425304, 546119, 546121, 544127, 544362
Abstract:
The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I.
Substituted Quinolines And Their Uses In Treatment Of Inflammatory And Related Conditions
View pageUS Patent:
7705018, Apr 27, 2010
Filed:
Mar 24, 2008
Appl. No.:
12/079322
Inventors:
Yi Chen - San Mateo CA, US
Timothy D. Cushing - Pacifica CA, US
Xiaolin Hao - Foster City CA, US
Xiao He - Foster City CA, US
Andreas Reichelt - Moorpark CA, US
Robert M. Rzasa - Ventura CA, US
Jennifer Seganish - Garwood NJ, US
Youngsook Shin - Emeryville CA, US
Dawei Zhang - Thousand Oaks CA, US
Timothy D. Cushing - Pacifica CA, US
Xiaolin Hao - Foster City CA, US
Xiao He - Foster City CA, US
Andreas Reichelt - Moorpark CA, US
Robert M. Rzasa - Ventura CA, US
Jennifer Seganish - Garwood NJ, US
Youngsook Shin - Emeryville CA, US
Dawei Zhang - Thousand Oaks CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
A61K 31/47
US Classification:
514314, 544333, 546167
Abstract:
Substituted bicyclic heteroaryls having the general formula.
Phthalazine Compounds And Methods Of Use
View pageUS Patent:
7759337, Jul 20, 2010
Filed:
Mar 2, 2006
Appl. No.:
11/367123
Inventors:
Andrew Tasker - Simi Valley CA, US
Dawei Zhang - Thousand Oaks CA, US
Guo-Qiang Cao - Thousand Oaks CA, US
Partha Pratim Chakrabarti - Newbury Park CA, US
James Richard Falsey - Moorpark CA, US
Bradley J. Herberich - Newbury Park CA, US
Randall W. Hungate - Camarillo CA, US
Liping H. Pettus - Thousand Oaks CA, US
Anthony Reed - Oxnard CA, US
Robert M. Rzasa - Ventura CA, US
Kelvin K. C. Sham - Thousand Oaks CA, US
Maya C. Thaman - Ventura CA, US
Shimin Xu - Santa Barbara CA, US
Dawei Zhang - Thousand Oaks CA, US
Guo-Qiang Cao - Thousand Oaks CA, US
Partha Pratim Chakrabarti - Newbury Park CA, US
James Richard Falsey - Moorpark CA, US
Bradley J. Herberich - Newbury Park CA, US
Randall W. Hungate - Camarillo CA, US
Liping H. Pettus - Thousand Oaks CA, US
Anthony Reed - Oxnard CA, US
Robert M. Rzasa - Ventura CA, US
Kelvin K. C. Sham - Thousand Oaks CA, US
Maya C. Thaman - Ventura CA, US
Shimin Xu - Santa Barbara CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
C07D 237/34
C07D 413/12
C07D 498/08
C07D 279/12
C07D 243/08
A61K 31/498
A61K 31/5355
A61K 31/537
A61K 31/541
A61K 31/551
A61P 29/00
A61P 23/00
C07D 487/04
A61K 31/4985
C07D 413/12
C07D 498/08
C07D 279/12
C07D 243/08
A61K 31/498
A61K 31/5355
A61K 31/537
A61K 31/541
A61K 31/551
A61P 29/00
A61P 23/00
C07D 487/04
A61K 31/4985
US Classification:
514218, 5142345, 5142305, 5142282, 514248, 540492, 544237, 544119, 544105, 544 582, 544236
Abstract:
The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I.
Heterocyclic Modulators Of Pkb
View pageUS Patent:
7897619, Mar 1, 2011
Filed:
Jul 16, 2008
Appl. No.:
12/218754
Inventors:
Qingping Zeng - Thousand Oaks CA, US
Dawei Zhang - Thousand Oaks CA, US
Guomin Yao - Newbury Park CA, US
George E. Wohlhieter - Lake Balboa CA, US
Xianghong Wang - Moorpark CA, US
James Rider - Woodland Hills CA, US
Andreas Reichelt - Moorpark CA, US
Holger Monenschein - Camarillo CA, US
James R. Falsey - Moorpark CA, US
Celia Dominguez - Los Angeles CA, US
Matthew P. Bourbeau - Woodland Hills CA, US
John G. Allen - Newbury Park CA, US
Dawei Zhang - Thousand Oaks CA, US
Guomin Yao - Newbury Park CA, US
George E. Wohlhieter - Lake Balboa CA, US
Xianghong Wang - Moorpark CA, US
James Rider - Woodland Hills CA, US
Andreas Reichelt - Moorpark CA, US
Holger Monenschein - Camarillo CA, US
James R. Falsey - Moorpark CA, US
Celia Dominguez - Los Angeles CA, US
Matthew P. Bourbeau - Woodland Hills CA, US
John G. Allen - Newbury Park CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
A61K 31/47
A61K 31/416
C07D 217/02
C07D 231/56
A61K 31/416
C07D 217/02
C07D 231/56
US Classification:
514311, 544224, 544235, 544242, 544253, 544283, 546112, 546139, 546152, 546157, 5483601, 5483611, 5483027, 5483064, 514248, 514299, 514387, 514403
Abstract:
The invention relates to heterocyclic compounds of Formula I and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.
Substituted Pyrazolo[3,4-D]Pyrimidines As Pi3K Inhibitors
View pageUS Patent:
7919498, Apr 5, 2011
Filed:
Mar 24, 2008
Appl. No.:
12/079281
Inventors:
Yi Chen - San Mateo CA, US
Timothy D. Cushing - Pacifica CA, US
Xiaolin Hao - Foster City CA, US
Xiao He - Foster City CA, US
Andreas Reichelt - Moorpark CA, US
Robert M. Rzasa - Ventura CA, US
Jennifer Seganish - Garwood NJ, US
Youngsook Shin - Emeryville CA, US
Dawei Zhang - Thousand Oaks CA, US
Timothy D. Cushing - Pacifica CA, US
Xiaolin Hao - Foster City CA, US
Xiao He - Foster City CA, US
Andreas Reichelt - Moorpark CA, US
Robert M. Rzasa - Ventura CA, US
Jennifer Seganish - Garwood NJ, US
Youngsook Shin - Emeryville CA, US
Dawei Zhang - Thousand Oaks CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
C07D 487/04
A61K 31/519
A61P 19/02
A61P 29/00
A61K 31/519
A61P 19/02
A61P 29/00
US Classification:
5142621, 544262, 544280, 5142651
Abstract:
Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukemia (AML) Myelodysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.
Phthalazine Compounds And Methods Of Use
View pageUS Patent:
8101612, Jan 24, 2012
Filed:
Sep 4, 2007
Appl. No.:
11/899363
Inventors:
Andrew Tasker - Simi Valley CA, US
Dawei Zhang - Thousand Oaks CA, US
Liping H. Pettus - Thousand Oaks CA, US
Rob M. Rzasa - Ventura CA, US
Kelvin K. C. Sham - Thousand Oaks CA, US
Shimin Xu - Newbury Park CA, US
Partha Chakrabarti - Nagpur, IN
Dawei Zhang - Thousand Oaks CA, US
Liping H. Pettus - Thousand Oaks CA, US
Rob M. Rzasa - Ventura CA, US
Kelvin K. C. Sham - Thousand Oaks CA, US
Shimin Xu - Newbury Park CA, US
Partha Chakrabarti - Nagpur, IN
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
C07D 237/30
C07D 413/04
A61K 31/502
A61K 31/5355
A61P 29/00
A61P 19/02
A61P 19/10
A61P 17/06
A61P 17/00
A61P 31/00
A61P 31/16
A61P 31/22
A61P 37/08
A61P 21/00
A61P 3/10
A61P 9/10
A61P 33/06
C07D 413/04
A61K 31/502
A61K 31/5355
A61P 29/00
A61P 19/02
A61P 19/10
A61P 17/06
A61P 17/00
A61P 31/00
A61P 31/16
A61P 31/22
A61P 37/08
A61P 21/00
A61P 3/10
A61P 9/10
A61P 33/06
US Classification:
514248, 544237, 544116, 5142345
Abstract:
The present invention comprises a new class of compounds useful for the prophylaxis and treatment of p38 kinase mediated diseases and related inflammatory conditions. The compounds have a general Formula II.